Venture&Growth
Location
Munich, Germany
Edwin de Graaf
Managing Partner
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Ablative Solutions
US-based MedTech focused on treatment of hypertension via renal denervation.
Inari Medical
US MedTech company focused on removal of blood clots to treat pulmonary embolism or deep...
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
